{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:27:05Z","timestamp":1768271225998,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11060-024-04588-4","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T16:02:41Z","timestamp":1708099361000},"page":"211-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors"],"prefix":"10.1007","volume":"167","author":[{"given":"Lisa M.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Hoshina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyejung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Colman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9138-8658","authenticated-orcid":false,"given":"Joe","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"4588_CR1","doi-asserted-by":"publisher","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, National Cancer Institute of Canada Clinical Trials Group (2005) European Organisation for Research and Treatment of Cancer Brain Tumor Radiotherapy Groups, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987\u2013996 https:\/\/doi.org\/10.1056\/NEJMoa043330","DOI":"10.1056\/NEJMoa043330"},{"key":"4588_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG (2021) Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053\u2013\u200922054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22:813\u2013823. https:\/\/doi.org\/10.1016\/S1470-2045(21)00090-5","journal-title":"Lancet Oncol"},{"key":"4588_CR3","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/jco.2007.25.18_suppl.2012","volume":"25","author":"SA Grossman","year":"2007","unstructured":"Grossman SA, Desideri S, Ye X, Szajna K, Chamberlain M, Lesser G (2007) Iatrogenic immunosuppression in patients with newly diagnosed high-grade gliomas. J Clin Oncol 25:2012\u20132012. https:\/\/doi.org\/10.1200\/jco.2007.25.18_suppl.2012","journal-title":"J Clin Oncol"},{"key":"4588_CR4","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","volume":"17","author":"SA Grossman","year":"2011","unstructured":"Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S, Consortium NC (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473\u20135480. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0774","journal-title":"Clin Cancer Res"},{"key":"4588_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1023\/a:1024217527650","volume":"63","author":"AK Mahindra","year":"2003","unstructured":"Mahindra AK, Grossman SA (2003) Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 63:263\u2013270. https:\/\/doi.org\/10.1023\/a:1024217527650","journal-title":"J Neurooncol"},{"key":"4588_CR6","volume-title":"Temozolomide [package insert]","author":"Merck & Co","year":"2016","unstructured":"Merck & Co (2016) Temozolomide [package insert]. Whitehouse Station, NJ"},{"key":"4588_CR7","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.1158\/1078-0432.CCR-05-0722","volume":"11","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Pazdur R (2005) Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11:6767\u20136771. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0722","journal-title":"Clin Cancer Res"},{"key":"4588_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJM199104183241602","volume":"324","author":"B Hirschel","year":"1991","unstructured":"Hirschel B, Lazzarin A, Chopard P, Opravil M, Furrer HJ, Ruttimann S, Vernazza P, Chave JP, Ancarani F, Gabriel V et al (1991) A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 324:1079\u20131083. https:\/\/doi.org\/10.1056\/NEJM199104183241602","journal-title":"N Engl J Med"},{"key":"4588_CR9","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJM199212243272603","volume":"327","author":"MM Schneider","year":"1992","unstructured":"Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, Nielsen TL, van der Graaf Y, Frissen JP, van der Ende IM, Kolsters AF, Borleffs JC (1992) A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 327:1836\u20131841. https:\/\/doi.org\/10.1056\/NEJM199212243272603","journal-title":"N Engl J Med"},{"key":"4588_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1215\/15228517-2006-024","volume":"9","author":"DE Gerber","year":"2007","unstructured":"Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9:47\u201352. https:\/\/doi.org\/10.1215\/15228517-2006-024","journal-title":"Neuro Oncol"},{"key":"4588_CR11","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/neuonc\/noac072","volume":"24","author":"SA Climans","year":"2022","unstructured":"Climans SA, Grunfeld E, Mason WP, Chan KKW (2022) Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy. Neuro Oncol 24:1738\u20131748. https:\/\/doi.org\/10.1093\/neuonc\/noac072","journal-title":"Neuro Oncol"},{"key":"4588_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-007-9403-6","volume":"85","author":"N Singhal","year":"2007","unstructured":"Singhal N, Selva-Nayagam S, Brown MP (2007) Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. J Neurooncol 85:229\u2013230. https:\/\/doi.org\/10.1007\/s11060-007-9403-6","journal-title":"J Neurooncol"},{"key":"4588_CR13","unstructured":"Hoffmann-LaRoche (2013) Bactrim\u2122: sulfamethoxazole and trimethoprim DS (double-strength) tablets and tablets USP. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/017377s074lbl.pdf"},{"key":"4588_CR14","doi-asserted-by":"publisher","first-page":"AB25","DOI":"10.1016\/j.jaci.2017.12.078","volume":"141","author":"R Elajez","year":"2018","unstructured":"Elajez R, Adeli M (2018) Myelosuppression effect of trimethoprim-sulfamethoxazole prophylaxis in innate immune defect patients: retrospective comparative study. J Allergy Clin Immunol 141:AB25. https:\/\/doi.org\/10.1016\/j.jaci.2017.12.078","journal-title":"J Allergy Clin Immunol"},{"key":"4588_CR15","unstructured":"Lexicomp (n.d.) Pentamidine (oral inhalation): drug information. https:\/\/www.uptodate.com\/contents\/pentamidine-oral-inhalation-drug-information?search=pentamidine&source=panel_search_result&selectedTitle=1~58&usage_type=panel&showDrugLabel=true&display_rank=1#F44486498. Accessed January 13 2024"},{"key":"4588_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11060-009-9813-8","volume":"94","author":"JG Walker","year":"2009","unstructured":"Walker JG, Kadia T, Brown L, Juneja HS, de Groot JF (2009) Dapsone induced methemoglobinemia in a patient with glioblastoma. J Neurooncol 94:149\u2013152. https:\/\/doi.org\/10.1007\/s11060-009-9813-8","journal-title":"J Neurooncol"},{"key":"4588_CR17","doi-asserted-by":"publisher","first-page":"E76","DOI":"10.1002\/ajh.25379","volume":"94","author":"A Mitta","year":"2019","unstructured":"Mitta A, Curtis BR, Reese JA, George JN (2019) Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data. Am J Hematol 94:E76\u2013E78. https:\/\/doi.org\/10.1002\/ajh.25379","journal-title":"Am J Hematol"},{"key":"4588_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1215\/15228517-2008-120","volume":"11","author":"TS Armstrong","year":"2009","unstructured":"Armstrong TS, Cao Y, Scheurer ME, Vera-Bolanos E, Manning R, Okcu MF, Bondy M, Zhou R, Gilbert MR (2009) Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol 11:825\u2013832. https:\/\/doi.org\/10.1215\/15228517-2008-120","journal-title":"Neuro Oncol"},{"key":"4588_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1001\/archneur.1991.00530160074017","volume":"48","author":"JW Henson","year":"1991","unstructured":"Henson JW, Jalaj JK, Walker RW, Stover DE, Fels AO (1991) Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 48:406\u2013409. https:\/\/doi.org\/10.1001\/archneur.1991.00530160074017","journal-title":"Arch Neurol"},{"key":"4588_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/cns.14.24","volume":"3","author":"AJ Neuwelt","year":"2014","unstructured":"Neuwelt AJ, Nguyen TM, Fu R, Bubalo J, Tyson RM, Lacy C, Gahramanov S, Nasseri M, Barnes PD, Neuwelt EA (2014) Incidence of Pneumocystis Jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. CNS Oncol 3:267\u2013273. https:\/\/doi.org\/10.2217\/cns.14.24","journal-title":"CNS Oncol"},{"key":"4588_CR21","doi-asserted-by":"publisher","first-page":"116431","DOI":"10.1016\/j.jns.2019.116431","volume":"405","author":"N Rifino","year":"2019","unstructured":"Rifino N, Rigamonti A, Guida FM, De Nobili G, Spena G, Ferrarese C, Salmaggi A (2019) Lack of development of Pneumocystis Jirovecii Pneumonia in a cohort of 103 Italian glioblastoma patients not receiving prophylaxis during post-surgical chemoradiotherapy. J Neurol Sci 405:116431. https:\/\/doi.org\/10.1016\/j.jns.2019.116431","journal-title":"J Neurol Sci"},{"key":"4588_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/nop\/npy049","volume":"6","author":"N Skorupan","year":"2019","unstructured":"Skorupan N, Ranjan S, Mehta S, Yankulina O, Nenortas N, Grossman S, Ye X, Holdhoff M (2019) Pneumocystis jirovecii prophylaxis in patients treated for high-grade gliomas: a survey among neuro-oncologists. Neurooncol Pract 6:321\u2013326. https:\/\/doi.org\/10.1093\/nop\/npy049","journal-title":"Neurooncol Pract"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04588-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T12:09:37Z","timestamp":1711627777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04588-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["4588"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04588-4","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the Institutional Review Board at the University of Utah.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study was performed with a waiver of informed consent from the Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was performed with a waiver of informed consent from the Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}